Arturo Molina, MD
Known title: Chief Medical OfficerCIK: 0001398940
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Sutro Biopharma Names New Business Development SVP. Sutro Biopharma has appointed Lucas Donigian as Senior Vice President of Business Development. This leadership addition is relevant for investors tracking the company's commercial strategy and partnership efforts. The move provides context for the stock's current trading levels and analyst expectations.
Transaction History
| PTGX | ▼ Sell | Open Market | 15,000 | $1.6M | 3/26/2026 | View on chart |
| PTGX | ▲ Buy | Option Exercise | 15,000 | $121K | 3/26/2026 | View on chart |
| PTGX | ▲ Buy | Option Exercise | 5,000 | $40K | 1/27/2026 | View on chart |
| PTGX | ▼ Sell | Open Market | 5,000 | $410K | 1/27/2026 | View on chart |
| PTGX | ▲ Buy | Option Exercise | 5,000 | $40K | 1/26/2026 | View on chart |
| PTGX | ▼ Sell | Open Market | 5,000 | $411K | 1/26/2026 | View on chart |
| PTGX | ▼ Sell | Open Market | 13,151 | $1.1M | 1/23/2026 | View on chart |
| PTGX | ▼ Sell | Open Market | 9,514 | $785K | 1/20/2026 | View on chart |
| PTGX | ▲ Buy | Grant | 25,600 | $0 | 1/2/2026 | View on chart |
| PTGX | ▼ Sell | Open Market | 2,712 | $230K | 11/17/2025 | View on chart |
| PTGX | ▲ Buy | Option Exercise | 10,000 | $80K | 6/10/2025 | View on chart |
| PTGX | ▼ Sell | Open Market | 10,000 | $570K | 6/10/2025 | View on chart |
| PTGX | ▼ Sell | Open Market | 10,000 | $555K | 6/9/2025 | View on chart |
| PTGX | ▲ Buy | Option Exercise | 10,000 | $80K | 6/9/2025 | View on chart |
| PTGX | ▲ Buy | Option Exercise | 28,437 | $666K | 3/13/2025 | View on chart |
| PTGX | ▲ Buy | Option Exercise | 2,077 | $81K | 3/13/2025 | View on chart |
| PTGX | ▼ Sell | Open Market | 30,514 | $1.7M | 3/13/2025 | View on chart |
| PTGX | ▼ Sell | Open Market | 388 | $0 | 1/16/2025 | View on chart |
| PTGX | ▼ Sell | Open Market | 3,252 | $0 | 1/16/2025 | View on chart |
| PTGX | ▲ Buy | Grant | 41,088 | $0 | 1/2/2025 | View on chart |
| PTGX | ▲ Buy | Option Exercise | 10,000 | $80K | 11/27/2024 | View on chart |
| PTGX | ▼ Sell | Open Market | 10,000 | $445K | 11/27/2024 | View on chart |
| PTGX | ▲ Buy | Option Exercise | 16,000 | $129K | 11/27/2024 | View on chart |
| PTGX | ▼ Sell | Open Market | 16,000 | $717K | 11/27/2024 | View on chart |
| PTGX | ▲ Buy | Option Exercise | 5,529 | $44K | 11/26/2024 | View on chart |
| PTGX | ▼ Sell | Open Market | 5,529 | $252K | 11/26/2024 | View on chart |
| PTGX | ▼ Sell | Open Market | 1,906 | $78K | 11/15/2024 | View on chart |
| PTGX | ▼ Sell | Tax Withholding | 427 | $11K | 1/16/2024 | View on chart |
| PTGX | ▲ Buy | Grant | 26,250 | $0 | 1/2/2024 | View on chart |
| PTGX | ▼ Sell | Open Market | 1,848 | $30K | 11/15/2023 | View on chart |
| PTGX | ▲ Buy | Grant | 3,125 | $0 | 1/16/2023 | View on chart |
| PTGX | ▲ Buy | Grant | 21,250 | $0 | 11/15/2022 | View on chart |
| STRO | ▲ Buy | Option Exercise | 12,500 | — | 3/5/2022 | View on chart |
| STRO | ▼ Sell | Tax Withholding | 4,355 | $36K | 3/5/2022 | View on chart |
| STRO | ▼ Sell | Tax Withholding | 2,151 | $22K | 1/29/2022 | View on chart |
| STRO | ▲ Buy | Option Exercise | 5,250 | $0 | 1/29/2022 | View on chart |
| STRO | ▼ Sell | Tax Withholding | 2,976 | $57K | 9/24/2021 | View on chart |
| STRO | ▲ Buy | Option Exercise | 8,609 | $0 | 9/24/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
PTGX featured in recent SeekingAlpha and Benzinga articles
A SeekingAlpha column noted Johnson & Johnson’s strong catalysts while keeping a hold stance, a view that may influence sentiment toward biotech peers such as Protagonist Therapeutics. Separately, Benzinga published a piece examining how a $100 investment in PTGX ten years ago would have grown, highlighting the stock’s historical performance. These mentions reflect ongoing analyst and investor interest in the company.
PTGX featured in recent SeekingAlpha and Benzinga articles. A SeekingAlpha column noted Johnson & Johnson’s strong catalysts while keeping a hold stance, a view that may influence sentiment toward biotech peers such as Protagonist Therapeutics. Separately, Benzinga published a piece examining how a $100 investment in PTGX ten years ago would have grown, highlighting the stock’s historical performance. These mentions reflect ongoing analyst and investor interest in the company.